Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Teva Pharmaceutical Industries Ltd Announces Launch Of Generic Symbyax In United States
Teva Pharmaceutical Industries Ltd announced the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company’s generic equivalent of Symbyax. Symbyax is marketed by Lilly USA and approved for the acute treatment of treatment resistant depression and bipolar I depression in adults.
Latest Developments for Teva Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402
- FDA Approves New Drug Application For Teva Pharmaceutical Industries Ltd's Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets For Prevention Of Pregnancy
- Teva Pharmaceutical Industries Ltd And H. Lundbeck A/S Announces Results Of Azilect
- Teva Pharmaceutical Industries Ltd Reaffirms FY 2013 Guidance; Comments On H1, H2 Revenue Guidance-Conference Call
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters